CN103356969A - Traditional Chinese medicine composition for treating hysteromyoma - Google Patents
Traditional Chinese medicine composition for treating hysteromyoma Download PDFInfo
- Publication number
- CN103356969A CN103356969A CN201310329131XA CN201310329131A CN103356969A CN 103356969 A CN103356969 A CN 103356969A CN 201310329131X A CN201310329131X A CN 201310329131XA CN 201310329131 A CN201310329131 A CN 201310329131A CN 103356969 A CN103356969 A CN 103356969A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating hysteromyoma. The composition is prepared from the following raw materials, by weight, 25-35 parts of safflowers, 25-35 parts of frankincense, 25-35 parts of myrrh, 15-25 parts of radix codonopsis, 10-20 parts of bighead atractylodes rhizome, 10-20 parts of achyranthes roots, 10-20 parts of salvia miltiorrhiza, 10-20 parts of tangerine seeds, 10-20 parts of subprostrate sophora, 10-20 parts of lychee seeds, 10-15 parts of seaweed, 10-15 parts of oyster, 10-15 parts of rhizoma sparganii, 10-15 parts of curcuma zedoary, 7-13 parts of cassia twig, 7-13 parts of poria cocos, 7-13 parts of peach seeds, 7-13 parts of tree peony bark, 7-13 parts of red paeony roots, 7-13 parts of turtle shells, 7-13 parts of selaginella tamariscina, 7-13 parts of green tangerine peel, 7-13 parts of teasel roots, 7-13 parts of radix astragali, 7-13 parts of phellodendron, 7-13 parts of edible tulip and 7-13 parts of cyperus rotundus. The traditional Chinese medicine composition has advantages of stable curative effects, short curative time and minimal side effects.
Description
Technical field
The present invention relates to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine composition for the treatment of hysteromyoma.
Background technology
Hysteromyoma is the modal benign tumors of female sex organs, also is the modal tumor of human body, mainly by smoothly
Myocyte's hypertrophy forms, and a small amount of fibrous connective tissue is arranged therebetween.Be common in 30 ~ 50 years old women, rare below 20 years old.According to statistics, have at least 20% the women of child-bearing age to suffer from hysteromyoma.The many non-evident symptons of most of hysteromyoma only chance on when health check-up.Have the symptom with muscular tumor position, size, have or not degeneration etc. relevant.Common sympton has: menorrhagia, and dysmenorrhea, leukorrhagia, abdominal mass, infertile, the symptoms such as anemia.
At present, the medicine for the treatment of hysteromyoma is more, but has the deficiencies such as curative effect is unstable, treatment time is long, side effect is large.
Summary of the invention
The technical problem to be solved in the present invention is: for solving the deficiencies in the prior art, the invention provides a kind of Chinese medicine composition for the treatment of hysteromyoma, the present invention has stable curative effect, treatment time is short, side effect is little advantage.
A kind of Chinese medicine composition for the treatment of hysteromyoma, crude drug by following weight portion is made: Flos Carthami 25-35 part, Olibanum 25-35 part, Myrrha 25-35 part, Radix Codonopsis 15-25 part, Rhizoma Atractylodis Macrocephalae 10-20 part, Radix Achyranthis Bidentatae 10-20 part, Radix Salviae Miltiorrhizae 10-20 part, Semen Citri Reticulatae 10-20 part, Radix Sophorae Tonkinensis 10-20 part, Semen Litchi 10-20 part, Sargassum 10-15 part, Concha Ostreae 10-15 part, rhizoma sparganic 10-15 part, Rhizoma Curcumae 10-15 part, Ramulus Cinnamomi 7-13 part, Poria 7-13 part, Semen Persicae 7-13 part, Cortex Moutan 7-13 part, Radix Paeoniae Rubra 7-13 part, Carapax Trionycis 7-13 part, Herba Selaginellae 7-13 part, Pericarpium Citri Reticulatae Viride 7-13 part, Radix Dipsaci 7-13 part, each 7-13 part of the Radix Astragali, Cortex Phellodendri 7-13 part, Pseudobulbus Cremastrae Seu Pleiones 7-13 part, Rhizoma Cyperi 7-13 part.
The Chinese medicine composition of described treatment hysteromyoma, it preferably, crude drug by following weight portion is made: 30 parts on Flos Carthami, 30 parts of Olibanums, 30 parts of Myrrhas, 20 parts of Radix Codonopsis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Radix Achyranthis Bidentataes, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Semen Citri Reticulataes, 15 parts of Radix Sophorae Tonkinensiss, 15 parts of Semen Litchis, 12 parts of Sargassums, 12 parts of Concha Ostreaes, 12 parts of rhizoma sparganic, 12 parts of Rhizoma Curcumae, 10 parts of Ramulus Cinnamomi, 10 parts in Poria, 10 parts in Semen Persicae, 10 parts of Cortex Moutans, 10 parts of Radix Paeoniae Rubra, 10 parts of Carapax Trionycis, 10 parts of Herba Selaginellaes, 10 parts on Pericarpium Citri Reticulatae Viride, 10 parts of Radix Dipsacis, each 10 parts of the Radixs Astragali, 10 parts of Cortex Phellodendris, 10 parts of Pseudobulbus Cremastrae Seu Pleioness, 10 parts of Rhizoma Cyperis.
The preparation method of the Chinese medicine composition of described treatment hysteromyoma is: Chinese medicinal preparation method is routinely made and is suitable for medicinal oral drugs.
The application of the Chinese medicine composition of described treatment hysteromyoma in preparation treatment hysteromyoma medicine.
The beneficial effect that the present invention compared with prior art has is: the present invention is under Traditional Chinese medical theory and clinical experience guidance, chooses each crude drug and proportioning thereof, has the function of replenishing QI to invigorate the spleen, eliminating blood stasis and smoothing collaterals, realizes the purpose for the treatment of hysteromyoma.
Below in conjunction with clinical experiment beneficial effect of the present invention is described:
(1) clinical data: the present invention treats patients with uterine myoma 68 examples altogether, and the age is 28-50 year.
(2) Therapeutic Method: the oral drugs that Chinese medicine composition of the present invention is made can be decoction, tablet, pill and capsule etc., take decoction as example, take 1 pair of every day minutes for 2 times, and early, respectively take 1 time evening, 20 days is 1 course for the treatment of.
(3) the standard of curative effect evaluation:
Cure: clinical symptom disappearance, muscular tumor disappears, the eumenorrhea;
Produce effects: eumenorrhea, or the change of muscular tumor disappearance menstrual symptom thing, muscular tumor is dwindled>0.5cm;
Effectively: clinical symptom relief or disappearance, muscular tumor is dwindled, and menstruation is unchanged without improvement or muscular tumor, the eumenorrhea; Invalid: the unchanged or increase of muscular tumor, menstruation is without change.
(4) therapeutic outcome: the present invention treats patients with uterine myoma 68 examples altogether, through 1-3 course of therapy, cures 49 examples, accounts for 72.1%, and produce effects 9 examples account for 13.2%, and effective 6 examples account for 8.8%, and invalid 4 examples account for 5.9%, and effective percentage is 94.1%, has no any side effect; Cure in 49 examples, cure 15 examples 1 course for the treatment of, cure 18 examples 2 courses for the treatment of, cure 16 examples 3 courses for the treatment of, follows up a case by regular visits to half after the healing by 1 year, is showed no recurrence; The result shows, the present invention has stable curative effect, treatment time is short, side effect is little advantage.
The specific embodiment
Embodiment 1:
A kind of Chinese medicine composition for the treatment of hysteromyoma, crude drug by following weight portion is made: 30 parts on Flos Carthami, 30 parts of Olibanums, 30 parts of Myrrhas, 20 parts of Radix Codonopsis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Radix Achyranthis Bidentataes, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Semen Citri Reticulataes, 15 parts of Radix Sophorae Tonkinensiss, 15 parts of Semen Litchis, 12 parts of Sargassums, 12 parts of Concha Ostreaes, 12 parts of rhizoma sparganic, 12 parts of Rhizoma Curcumae, 10 parts of Ramulus Cinnamomi, 10 parts in Poria, 10 parts in Semen Persicae, 10 parts of Cortex Moutans, 10 parts of Radix Paeoniae Rubra, 10 parts of Carapax Trionycis, 10 parts of Herba Selaginellaes, 10 parts on Pericarpium Citri Reticulatae Viride, 10 parts of Radix Dipsacis, each 10 parts of the Radixs Astragali, 10 parts of Cortex Phellodendris, 10 parts of Pseudobulbus Cremastrae Seu Pleioness, 10 parts of Rhizoma Cyperis.
Its preparation method is: Chinese medicinal preparation method is routinely made and is suitable for medicinal oral drugs.
Embodiment 2:
A kind of Chinese medicine composition for the treatment of hysteromyoma, crude drug by following weight portion is made: 25 parts on Flos Carthami, 25 parts of Olibanums, 25 parts of Myrrhas, 15 parts of Radix Codonopsis, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Achyranthis Bidentataes, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Semen Citri Reticulataes, 10 parts of Radix Sophorae Tonkinensiss, 10 parts of Semen Litchis, 10 parts of Sargassums, 10 parts of Concha Ostreaes, 10 parts of rhizoma sparganic, 10 parts of Rhizoma Curcumae, 7 parts of Ramulus Cinnamomi, 7 parts in Poria, 7 parts in Semen Persicae, 7 parts of Cortex Moutans, 7 parts of Radix Paeoniae Rubra, 7 parts of Carapax Trionycis, 7 parts of Herba Selaginellaes, 7 parts on Pericarpium Citri Reticulatae Viride, 7 parts of Radix Dipsacis, each 7 parts of the Radixs Astragali, 7 parts of Cortex Phellodendris, 7 parts of Pseudobulbus Cremastrae Seu Pleioness, 7 parts of Rhizoma Cyperis.
Its preparation method is: Chinese medicinal preparation method is routinely made and is suitable for medicinal oral drugs.
Embodiment 3:
A kind of Chinese medicine composition for the treatment of hysteromyoma, crude drug by following weight portion is made: 35 parts on Flos Carthami, 35 parts of Olibanums, 35 parts of Myrrhas, 25 parts of Radix Codonopsis, 20 parts of the Rhizoma Atractylodis Macrocephalaes, 20 parts of Radix Achyranthis Bidentataes, 20 parts of Radix Salviae Miltiorrhizaes, 20 parts of Semen Citri Reticulataes, 20 parts of Radix Sophorae Tonkinensiss, 20 parts of Semen Litchis, 15 parts of Sargassums, 15 parts of Concha Ostreaes, 15 parts of rhizoma sparganic, 15 parts of Rhizoma Curcumae, 13 parts of Ramulus Cinnamomi, 13 parts in Poria, 13 parts in Semen Persicae, 13 parts of Cortex Moutans, 13 parts of Radix Paeoniae Rubra, 13 parts of Carapax Trionycis, 13 parts of Herba Selaginellaes, 13 parts on Pericarpium Citri Reticulatae Viride, 13 parts of Radix Dipsacis, each 13 parts of the Radixs Astragali, 13 parts of Cortex Phellodendris, 13 parts of Pseudobulbus Cremastrae Seu Pleioness, 13 parts of Rhizoma Cyperis.
Its preparation method is: Chinese medicinal preparation method is routinely made and is suitable for medicinal oral drugs.
Claims (4)
1. Chinese medicine composition for the treatment of hysteromyoma, it is characterized in that: the crude drug by following weight portion is made: Flos Carthami 25-35 part, Olibanum 25-35 part, Myrrha 25-35 part, Radix Codonopsis 15-25 part, Rhizoma Atractylodis Macrocephalae 10-20 part, Radix Achyranthis Bidentatae 10-20 part, Radix Salviae Miltiorrhizae 10-20 part, Semen Citri Reticulatae 10-20 part, Radix Sophorae Tonkinensis 10-20 part, Semen Litchi 10-20 part, Sargassum 10-15 part, Concha Ostreae 10-15 part, rhizoma sparganic 10-15 part, Rhizoma Curcumae 10-15 part, Ramulus Cinnamomi 7-13 part, Poria 7-13 part, Semen Persicae 7-13 part, Cortex Moutan 7-13 part, Radix Paeoniae Rubra 7-13 part, Carapax Trionycis 7-13 part, Herba Selaginellae 7-13 part, Pericarpium Citri Reticulatae Viride 7-13 part, Radix Dipsaci 7-13 part, each 7-13 part of the Radix Astragali, Cortex Phellodendri 7-13 part, Pseudobulbus Cremastrae Seu Pleiones 7-13 part, Rhizoma Cyperi 7-13 part.
2. the Chinese medicine composition for the treatment of hysteromyoma according to claim 1, it is characterized in that: the crude drug by following weight portion is made: 30 parts on Flos Carthami, 30 parts of Olibanums, 30 parts of Myrrhas, 20 parts of Radix Codonopsis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Radix Achyranthis Bidentataes, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Semen Citri Reticulataes, 15 parts of Radix Sophorae Tonkinensiss, 15 parts of Semen Litchis, 12 parts of Sargassums, 12 parts of Concha Ostreaes, 12 parts of rhizoma sparganic, 12 parts of Rhizoma Curcumae, 10 parts of Ramulus Cinnamomi, 10 parts in Poria, 10 parts in Semen Persicae, 10 parts of Cortex Moutans, 10 parts of Radix Paeoniae Rubra, 10 parts of Carapax Trionycis, 10 parts of Herba Selaginellaes, 10 parts on Pericarpium Citri Reticulatae Viride, 10 parts of Radix Dipsacis, each 10 parts of the Radixs Astragali, 10 parts of Cortex Phellodendris, 10 parts of Pseudobulbus Cremastrae Seu Pleioness, 10 parts of Rhizoma Cyperis.
3. the preparation method of the Chinese medicine composition for the treatment of hysteromyoma according to claim 1 and 2, it is characterized in that: Chinese medicinal preparation method is routinely made and is suitable for medicinal oral drugs.
4. the application of the Chinese medicine composition for the treatment of hysteromyoma according to claim 1 and 2 in preparation treatment hysteromyoma medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310329131XA CN103356969A (en) | 2013-07-26 | 2013-07-26 | Traditional Chinese medicine composition for treating hysteromyoma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310329131XA CN103356969A (en) | 2013-07-26 | 2013-07-26 | Traditional Chinese medicine composition for treating hysteromyoma |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103356969A true CN103356969A (en) | 2013-10-23 |
Family
ID=49359771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310329131XA Pending CN103356969A (en) | 2013-07-26 | 2013-07-26 | Traditional Chinese medicine composition for treating hysteromyoma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103356969A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770818A (en) * | 2016-04-12 | 2016-07-20 | 姜丽莎 | Traditional Chinese medicine composition for treating uterine fibroid |
CN105998421A (en) * | 2016-07-18 | 2016-10-12 | 孟广千 | Traditional Chinese medicine composition for treating hysteromyoma |
CN106139008A (en) * | 2016-08-01 | 2016-11-23 | 南京市中医院 | A kind of Chinese medicine composition treating hysteromyoma |
CN107335009A (en) * | 2017-06-22 | 2017-11-10 | 邓高丕 | A kind of dissipating bind blood-nourishing herbal paste and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101322820A (en) * | 2008-07-28 | 2008-12-17 | 河南太龙药业股份有限公司 | Chinese medicine compound composition for treating gynecology hysteromyoma and pelvic inflammation mass |
CN101632820A (en) * | 2008-07-24 | 2010-01-27 | 郭纯 | Intestinal obstruction removal pill |
CN102068641A (en) * | 2010-10-09 | 2011-05-25 | 李蕴 | Chinese medicinal capsules for treating gynecological diseases |
-
2013
- 2013-07-26 CN CN201310329131XA patent/CN103356969A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101632820A (en) * | 2008-07-24 | 2010-01-27 | 郭纯 | Intestinal obstruction removal pill |
CN101322820A (en) * | 2008-07-28 | 2008-12-17 | 河南太龙药业股份有限公司 | Chinese medicine compound composition for treating gynecology hysteromyoma and pelvic inflammation mass |
CN102068641A (en) * | 2010-10-09 | 2011-05-25 | 李蕴 | Chinese medicinal capsules for treating gynecological diseases |
Non-Patent Citations (4)
Title |
---|
华占福;等: "治疗子宫肌瘤60例临床观察", 《甘肃中医学院学报》 * |
李欣: "自拟消瘤方配合大黄蟅虫丸治疗子宫肌瘤120 例疗效观察", 《中外医学研究》 * |
郝瑞芳: "桂枝茯苓丸加减治疗子宫肌瘤66例临床观察", 《中国医药指南》 * |
陈淑音: "加味桂枝茯苓丸治疗早期子宫肌瘤98例", 《陕西中医》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770818A (en) * | 2016-04-12 | 2016-07-20 | 姜丽莎 | Traditional Chinese medicine composition for treating uterine fibroid |
CN105998421A (en) * | 2016-07-18 | 2016-10-12 | 孟广千 | Traditional Chinese medicine composition for treating hysteromyoma |
CN106139008A (en) * | 2016-08-01 | 2016-11-23 | 南京市中医院 | A kind of Chinese medicine composition treating hysteromyoma |
CN107335009A (en) * | 2017-06-22 | 2017-11-10 | 邓高丕 | A kind of dissipating bind blood-nourishing herbal paste and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102151325B (en) | Traditional Chinese medicine for treating breast diseases | |
CN103356961B (en) | Traditional Chinese medicinal composition for treating amenorrhoea | |
CN103705866A (en) | Traditional Chinese medicine composition for treating hypomenorrhea | |
CN103784887A (en) | Traditional Chinese medicinal composition for treating kidney deficiency lumbago | |
CN102188583A (en) | Traditional Chinese medicine for treating infertility | |
CN104161868A (en) | Drug for treating rheumatoid arthritis | |
CN103356916A (en) | Traditional Chinese medicinal composition for treating retrograde menstruation | |
CN103356969A (en) | Traditional Chinese medicine composition for treating hysteromyoma | |
CN103356968B (en) | Traditional Chinese medicine composition for treating endometriosis | |
CN102198243B (en) | Oviduct dredging medicament for removing blood stasis and warming meridians | |
CN103330864A (en) | Traditional Chinese medicine composition used for treating acute nephritis and preparation method thereof | |
CN103446554A (en) | Traditional Chinese medicine composition for treating scapulohumeral periarthritis | |
CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
CN104173565A (en) | Traditional Chinese medicine composition for treating irregular menstruation | |
CN102579966A (en) | Traditional Chinese medicinal composition for treating uterine leiomyoma | |
CN103845620A (en) | Traditional Chinese medicine for treating raynaud disease | |
CN104043053A (en) | Traditional Chinese medicine for treating dysmenorrhea | |
CN103356925A (en) | Traditional Chinese medicine composition for treating sperm non-liquified symptom | |
CN104042970A (en) | Traditional Chinese medicine (TCM) composition for allergic purpura | |
CN101518607A (en) | Traditional Chinese medicine for treating carcinoma of kidney | |
CN104258272A (en) | Traditional Chinese medicine for treating nodules of breast | |
CN104383097A (en) | Traditional Chinese medicine for treating lupus erythematosus | |
CN103800664A (en) | Traditional Chinese medicine composition for treating menopausal syndrome | |
CN104042739A (en) | Traditional Chinese medicine for treating prospermia | |
CN103751418A (en) | Traditional Chinese medicine composition for treating restless leg syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131023 |